Stocks
Merck Stock Ticks Down Amid Positive Pipeline News
Merck & Co.'s stock was trading at EUR 128.34 on October 1, 2026 at 12:03 p.m. CEST, marking a 0.04 percent decline from its prior close of EUR 128.39.
This slight dip comes as the company announced positive results for its experimental treatment tulisokibart in a Phase 2b study for moderate to severe hidradenitis suppurativa.
Tulisokibart met both its primary and key secondary endpoints, according to Merck's September 30, 2026 announcement.
This development adds pipeline evidence to the pharmaceutical company's efforts to expand beyond established oncology products.